2023 Poster Presentations Coming in November


2022 Poster Presentations:

POSTER SESSION A - Monday, 14 November  ~ In-Person, Verdi/Vivaldi

A1: Developability: Evaluating Multiple Parameters for Effective Lead Candidate Selection, Presented by Arron H., Abzena

A2: One Scaffold, Several Approaches: Tackling Cancer Diseases with Nanofitins, Presented by Mathieu C., Affilogic

A3: Transferrin Receptor 1-Targeting Bicycles: A New Platform for Transcytosis, Presented by Haw L., Bicycle Therapeutics

A4: Is there a Real Solution for the Therapeutic mAbs Patent Cliff?, Presented by Paula GL., BioClonal

A5: 1C3, a Differentiated Non-Blocking Agonist TNFR2 Antibody for Cancer Immunotherapy, Presented by Jie H., Biocytogen Pharmaceuticals (Beijing) Co. Ltd.

A6: A Novel TCR Mimic Fully Human Antibodies Discovery Platform, Presented by Kaiqing Z., Biocytogen Pharmaceuticals (Beijing) Co. Ltd.

A7: Pipeline for Phage Display Screening of Peptide Ligands Targeting Scavenger Receptors, Presented by Olivia M., BioMed X GmbH

A8: Improving the Screening, Selection and Deep Characterization of Biotherapeutic Molecules Using High-Throughput SPR, Presented by Judicael P., Carterra

A9: Modeling Protein Properties Using pH-Dependent Conformational Sampling, Presented by Nels T., Chemical Computing Group

A10: Evaluation of New Technologies for the Characterization of AAV-Drug Products: Mass Photometry (MP), Asymmetric Flow Field Flow Fractionation (AF4), Microfluidic Resistive Pulse Sensing (MRPS), Presented by Cornelia Z., Coriolis Pharma Research GmbH

A11: Biomolecular Interaction Analysis with Grating-Coupled Interferometry (GCI), Presented by Tatiana T., Creoptix AG, a Malvern Panalytical brand

A12: CB307: A Novel T-Cell Costimulatory Humabody® V[H] Therapeutic for PSMA-Positive Tumours, Presented by Lorraine T., Crescendo Biologics

A13: GRIP Display: A One-Pot In Vitro Library Display Platform for Directed Evolution of Proteins, Presented by Victoria G., Duke University

A14: Human IgG Fc Production Through Methanol-Free Pichia pastoris Fermentation, Presented by Ying Y., Eppendorf, Inc.

A15: Ready-to-Use Cell-Based Assays to Enable Immunotherapy Drug Development for Checkpoint Receptors, Presented by Andrew G., Eurofins DiscoverX

A16: From DNA Transfection to GMP Manufacturing, Presented by Jean T., ExcellGene, SA

A17: Design of Experiment, a Powerful Tool to Simplify Viral Production Process Development, Presented by Anna D., Exothera

A18: Equine Polyclonal Antibodies Immunotherapy Against COVID-19/SARS-CoV2-VOC, Presented by Anais B., Fab’entech

A19: Application of Gene Editing Technologies to Improve Biotherapeutic Manufacturing, Presented by Mario P., Horizon Discovery Ltd.

A20: CHOSOURCE ADCC+ Cell Line for Enhanced Therapeutic Potency, Presented by Tulshi P., Horizon Discovery Ltd.

A21: A Stabilized HLA-B57 Open Format (IOS-1002) Binding to LILRB1, LILRB2 and KIR3DL1 Induces Potent Anti-Tumor Efficacy, Presented by Osiris MB., ImmunOs Therapeutics AG

A22: Selection of Human Antibodies for COVID-19 from an Immune Library Constructed with B Cells of the Convalescent Patients by Phage Display, Presented by Lilian T., Instituto Butantan

A23: Atomic-Level Specificity of Claudin 6 Monoclonal Antibodies Isolated for Treating Solid Tumors, Presented by Joseph R., Integral Molecular

A24: Think Globally: Improving Lonza’s XS® Pichia Production Platform by Systemic Engineering, Presented by Karlheinz F., Lonza

A25: An Agile Mass Spectrometry Approach to Monitor Residual Host Cell Proteins and Facilitate Decision-Making in Purification Process Development, Presented by Sabrina L., Lonza

A26: Discovery of Superior Functional Antibodies from Comprehensive Recombinant Antibody Repertoires, Presented by Matthieu D., Memo Therapeutics AG

A27: Assessing MHC-Associated Peptide Proteomics (MAPPs) Assay as a Tool to Predict Immunogenicity Potential of Protein Therapeutics in Preclinical Phase, Presented by Luca B., Merck Serono

A28: Automated Workflow for Screening of CRISPR-Edited Cell Lines; High Throughput Screening and Analysis of Monoclonality, Presented by Carola M., Molecular Devices LLC

A29: Developability Assessment of Early Stage Biotherapeutics - A Production Perspective, Presented by Stefan K., MorphoSys AG

A30: Novel Bioluminescent Bioassays for the Discovery and Development of Molecular and Cellular T Cell Redirecting Therapy, Presented by Julia G., Promega Corporation

A31: HiBiT: A Tiny Tag to Assess MOA-Based CAR-T Cell Potency, Presented by Gopal K., Promega Corporation

A32: Complex Glycoprotein Characterization Using ZipChip Followed by Protein Metrics Byos Data Interrogation, Presented by David L., Protein Metrics, Inc.

A33: T-SIGn® Viruses as a Strategy to Deliver Small Engineered Antibodies to the Tumour Microenvironment, Presented by Alice M., PsiOxus Therapeutics Ltd.

A34: Therapeutic Targeting of Senescence in Oncology and Fibrosis, Presented by Francesc M., Rejuveron Senescence Therapeutics AG

A35: rAAVolution - Towards Optimizing rAAV Production and Analytic Processes, Presented by Dennis K., Sartorius Xell GmbH

A36: Fast and Efficient Evaluation of the Impact of Fc N-Glycosylation on Antibody-Dependent Cellular Cytotoxicity, Presented by Therese S., Svar Life Science  

A37: Quantification of ADCP Activity of Therapeutic Antibodies Using Engineered Effector Cells and Target Cells, Presented by Michael S., Svar Life Science

A38: Synthetic Genetic Systems for Next Generation Biomedicines and Bioprocesses, Presented by Renata C., SynGenSys Ltd.

A39: TavoSelect VHO Discovery Platform, Presented by Maria M., Tavotek Biotherapeutics

A40: FKBP51 Transient Binding Pocket Stabilization by Protein Engineering, Presented by Jorge LR., Technical University of Darmstadt

A41: A Streamlined Process for the Generation of Humanized Multispecific Common Light Chain NK Cell-Engaging mABs, Presented by Michael U., Technical University of Darmstadt

A42: ORFeome Phage Display Reveals SARS-CoV-2 Related Immunogenic Epitope, Presented by Rico B., Technische Universitat Braunschweig

A43: Accelerating Advancement in Gene Therapy by Improving Downstream Purification of Viral Vectors, Presented by Hendrik A., Thermo Fisher Scientific

A44: Strategies for High-Titer Protein Expression Using the ExpiCHO and Expi293 Transient Expression Systems, Presented by Chao Yan L., Thermo Fisher Scientific

A45: Conformational Epitope Mapping of the Peanut Major Allergen Ara h 2, Presented by Zohar BS., Ukko, Inc.

A46: From Celiac Patients to Food Safety Assurance: Development of Novel Fabs for Gluten Detection in Food Matrix, Presented by Eduardo G-C., Universidad Complutense de Madrid

A47: Phage Display Selection of High-Affinity Peptides Against Calprotectin for Use as Synthetic Ligands in Diagnostic Assays, Presented by Cristina D-P., Universitat Ramon Llull

A48: Bicyclic Peptides for the Transport of Biotherapeutics Across the Blood-Brain Barrier, Presented by Maria L., Universitat Ramon Llull

A49: Evaluation of Urea and Glucose as Cryoprotective Agents in Human Mesenchymal Stem Cells, Presented by Markus K., University of Basel

A50: Identification of a Promising Anti-Mesothelin Fully Human scFv Showing Broad CAR and BiTE Potential for T-Cells Co-Engineering Applications, Presented by Johan A., University of Lausanne

A51: A Bispecific T Cell Engager Targeting the Stress-Related Antigen for Cytotoxicity and Tumour Microenvironment Remodelling, Presented by Peter W., University of Oxford

A52: Rapid and High Throughput IgG and Protein Aggregation Quantification in Crude Cell Culture Samples Using Multiwell Plates, Presented by Eligio I., Valitacell Ltd.



POSTER SESSION B Tuesday, 15 November ~ In-Person, Verdi/Vivaldi

B1: Prometheus 2.0™: Engineering Manufacturable Humanized Antibodies from Diverse Sources Including Rabbit, Avian and Camelid Antibodies, Presented by Donmienne L., Absolute Antibody

B2: AGEN1571 Is a Novel and Developable High-Affinity ILT2 Antagonist Antibody that Promotes Adaptive and Innate Immune Responses, Presented by Malgorzata P-S., Agenus UK Ltd.

B3: Antibody‑Mediated Delivery of a Viral MHC‑I Epitope into the Cytosol of Target Tumor Cells Repurposes Virus‑Specific CD8+T Cells for Cancer Immunotherapy, Presented by Deok‑Han K., Ajou University

B4: Immunomodulation of T- and NK-Cell Responses by a Bispecific Antibody Targeting CD28 Homolog and PD-L1, Presented by Zenon Z., AstraZeneca

B5: Non-Genotoxic Antibody-Based Conditioning Paired with Multi-Plex Base Edited HSCs for the Potential Treatment of Sickle Cell Disease, Presented by Kathy Z., Beam Therapeutics

B6: YH013, a Fully-Human EGFR X MET Bispecific ADC Exhibits Outstanding Specificity and Anti-Tumor Efficacy, Presented by Frank A., Biocytogen Pharmaceuticals (Beijing) Co. Ltd.

B7: Pioneer: A Novel Biotherapeutic Antibody Discovery Platform, Presented by Mateusz P., Bio-Rad Laboratories

B8: TrailBlazer: A Rapid Modular Antibody Assembly Platform, Presented by Katharina R., Bio-Rad Laboratories

B9: Characterization of Protein Based Biotherapeutics with Next-Generation MALDI Top-Down Sequencing, Presented by Christian A., Bruker Daltonics GmbH & Co. KG

B10: Engineering Strategies for Improvement of V[H]H Affinities Characterized by Bio-Layer Interferometry, Presented by Lorin D., Buehlmann Laboratories AG

B11: Extensive Sequence and Structural Evolution of Inhibitory Antibodies to Arginase2 Enabled by an Unbiased Approach to Affinity Maturation, Presented by Matthew C., Cancer Research Horizons

B12: Automated Real-Time Kinetic Rate Analysis of Antibodies Interacting with Living Cells Captured in Microfluidic Cell Traps, Presented by Nena M., Dynamic Biosensors GmbH

B13: Implementing MOA-Reflective ADCC Assays using Ready-to-Use KILR Target and Effector Cells from Screening to Lot Release, Presented by Francisca N., Eurofins DiscoverX

B14: Antibody Development and Quality Control by Mass Spectrometry, Presented by Desmond S., evitria AG

B15: Characterization of Bispecific Antibody Chain Pairing Variants by LC-MS at the Subunit Level, Presented by Andreas N., Genovis AB

B16: GlySERIAS Enables LC-MS Analysis of Fusion Proteins by Digesting Glycine-Rich Linkers, Presented by Jonathan S., Genovis AB

B17: CC-1, a Bispecific PSMAxCD3 Antibody for Treatment of Prostate Carcinoma: Results of the Ongoing Phase I Dose Escalation Trial, Presented by Martin P., German Cancer Consortium (DKTK)

B18: CC-3, an IgG-Based B7-H3xCD3 Bispecific Antibody for Targeting of Gastrointestinal Cancers, Presented by Helmut S., German Cancer Consortium (DKTK)

B19: How a Single Protein Tag Provides a Platform for Key Processes in Antibody Production, Presented by Fabian M., IBA Lifesciences GmbH

B20: Targeting KRAS[G12D] Cancer Neoantigen with Soluble High Affinity T Cell Receptor Bispecific, Presented by Chandramouli C., Immunocore Ltd.

B21: Targeted Immune Suppression via TCR PD-1 Agonist Bispecific Molecule (ImmTAAI) - A Novel Approach to Treat Type I Diabetes, Presented by David O., Immunocore Ltd.

B22: Isolation of Highly Selective Antibodies Against Claudin 18.2 and GPRC5D for Oncology Therapeutics, Presented by Sharon W., Integral Molecular

B23: In Vivo Evaluation of the Effects of Fc-Silencing Mutations on Antibody Half-Life Using FcRn Humanized Mouse Models, Presented by Adriano F., Jackson Laboratory

B24: Inducible Cas9 T Cells: An Innovative Platform for Allogeneic CAR T Cell Generation, Presented by Marian N., Lonza

B25: A High Performing Easy-to-Use Media and Feed System for CHOK1SV GS-KO® Cell Lines-Based Product Manufacturing, Presented by Deirdre R., Lonza

B26: MY006: A Novel Treatment for Peanut Allergy, Presented by Douglas P., Mabylon AG

B27: Double Mutation Near CDRs Reduces Antibody Aggregation Most Effectively, Presented by Minna M., Medix Biochemica

B28: Identification and Characterization of an Allogeneic iNKT-CAR Targeting BCMA, Presented by Efrat A-S., MiNK Therapeutics, Inc.

B29: The OmnidAb™ Platform: Chickens Expressing Heavy Chain-Only Antibodies, Presented by Christine V., OmniAb, Inc.

B30: Development and Validation of an Antibody-Drug Conjugate Bioassay, Presented by Louis L., Quality Assistance S.A.

B31: A Novel Trypsin for Accurate Characterisation of Biotherapeutic Proteins with Peptide Mapping, Presented by Cecile M., Quality Assistance S.A.

B32: Binding and Functional Characterization of Anti-HER2 Antibodies Using Advanced Flow Cytometry and BLI Label-Free Detection, Presented by Kirsty M., Sartorius (Essen Bioscience)

B33: AvidiMAb®, an Avidity-Enhancing Platform for Cancer Immunotherapy, Presented by Mireille V., Scancell Ltd.

B34: Use of Cyto-Mine to Expedite the Generation of Novel Biotherapeutics, Presented by Xin L., Sphere Fluidics Ltd.

B35: Detecting and Identifying Free Fatty Acid Breakdown Products of Surfactants Using Total Holographic Characterization, Presented by Laura P., Spheryx, Inc.

B36: Development of a Highly Sensitive ADCC iLite® Reporter Gene Assay with True MoA-Reflecting PropertiesPresented by Aida L., Svar Life Science

B37: Immune Library and Antibody Generation to Difficult Targets by Electro-Gene-Transfer, Presented by Giuseppe R., Takis Srl

B38: A Generic Strategy to Generate Trifunctional Two-in-One Antibodies by Chicken Immunization, Presented by Julia H., Technical University of Darmstadt

B39: Baitbody: Fc-Fusion Protein Application for Autoantibody Elimination in NMDAR Encephalitis, Presented by Stephan S., Technische Universitat Braunschweig

B40: Setting Up an Effective Protein Expression Workflow, Presented by Richard A., Thermo Fisher Scientific

B41: Accelerating Antibody Drug Development with Subdomain-Specific Affinity Chromatography, Presented by Kevin S., Thermo Fisher Scientific

B42: The Discovery, Engineering and Characterisation of a Highly Potent Anti-Human IL-22 Antibody Using a High-Throughput Single B-Cell Platform, Presented by John-Paul S., UCB Pharma

B43: Genomic and Proteomic Antibody Repertoire Analysis at Single-Cell and Single-Molecule Resolution, Presented by Khang LQ., Univ of Oslo

B44: The Evolving Landscape of Anti-CSC Antibody-Drug Conjugates: Challenges to Overcome, Presented by Montserrat ER., Universitat Ramon Llull

B45: Activatable Antibody Mimetics for the Selective Delivery of Therapeutics, Presented by Roberta L., Universitat Ramon Llull

B46: FlowSight® - An Imaging Flow Cytometer, Applicable for the Simultaneous Discrimination of Protein Particles and Silicone Oil Droplets in Pharmaceutical Formulations of Biologicals?, Presented by Ibrahim F., University Marburg

B47: A CXCL10-Based Biologic Which Mobilizes T-Cells Through Enhanced GAG-Binding, Presented by Tanja G., University of Graz

B48: Fluorination of Lipopolysaccharide for Detection by [19]F NMR, Presented by Amy G., University of Manchester

B49: Oncolytic Herpesvirus Expressing Bispecific Engager Targets T‐Cell Cytotoxicity to Immune Coinhibitory Checkpoint Molecules in Cancer Biopsies, Presented by Hena K., University of Oxford

B50: Gentle Site-Specific Labelling of scFv Antibodies for Time-Resolved Fluorescence-Based Immunoassays, Presented by Anastasiia K-V., University of Turku

B51: Deep Mutational Scanning for Fc Domain Engineering, Presented by Kyrin H., University of Waikato

B52: Upstream LC-MS Monitoring of Cell Culture and Microbial Growth Media Supporting Bioprocess Development, Presented by Nick P., Waters Corporation



POSTER SESSION C Wednesday, 16 November ~ In-Person, Verdi/Vivaldi

C1: Prepared for a Pandemic: Integrated Technologies Enable the Fastest Responses Against Novel Viral Outbreaks, Presented by Veronique L., AbCellera

C2: Redirecting T Cells to Tumor Targets with Functionally Diverse CD3-Binding Antibodies, Presented by Raffi T., AbCellera

C3: A Novel Asymmetric Anti-Claudin18.2xCD3 Bispecific Antibody, ABL603, Induces Potent Antitumor Activity with Lower Systemic Cytokine Release, Presented by Shinai L., ABL Bio, Inc.

C4: Tips and Tricks for Optimizing Intact Monoclonal Antibody Characterization, Presented by Andrea T., Agilent Technologies

C5: Engineering of α-Ketoglutaric Semialdehyde Dehydrogenase for Improving the Catalytic Activity of Converting 3-Hydroxypropanal into 3-Hydroxypropionic Acid, Presented by Sun Joo C., Ajou University

C6: Inducing Complete and Long-Lasting Tumor Eradications Using a Nectin-4 ADC Generated with a Novel Linker Technology, Presented by Romain B., Araris Biotech AG

C7: Interfacial Properties of BASF Surfactants for the Stabilization of Antibody Formulations, Presented by Nadine L., BASF SE

C8: Ultra High-Throughput pHLA Screen, Presented by Stefan K., BioCopy GmbH

C9: BiXAb®-Mediated MAIT Cell Redirection: Tumour Killing by Engagement of a Novel Innate Immune Subset, Presented by Julie P., Biomunex Pharmaceuticals

C10: Photodegradation of mAbs Under Visible Light Conditions, Presented by Patrick G., Boehringer Ingelheim Pharma GmbH & Co. KG

C11: CALIXAR'S Toolbox for Native Membrane Targets, Presented by Vincent C., CALIXAR

C12: Antibody-Drug Conjugate Off-Target Binding Screen: Increasing the Confidence in ADC Safety During Development, Presented by Diogo R., Charles River Labs

C13: Predicting Protein-Protein Binding Sites and Epitope Mapping, Presented by Sarah W., Chemical Computing Group

C14: Modern Sequential Experiment Design for Protein Discovery, Presented by Mojmir M., ETH Zurich

C15: Quantify Antibody-Dependent Cell Phagocytosis (ADCP): Application of a Robust, Non-Radioactive KILR Cytotoxicity Platform, Presented by Santosh S., Eurofins DiscoverX

C16: The Tetravalent Structure of FS118, a Bispecific Antibody Targeting LAG-3 and PD-L1, Is Required for Its Novel Mechanism of LAG-3 Shedding, Presented by Katy E., F star Therapeutics, Inc.

C17: Antibody Kinetics on Challenging Targets, Presented by Dennis V., Genmab B.V.

C18: Superior Tumor-Specificity Through Glycan-Dependent Protein Binding Antibodies, Presented by Manon W., Glycotope GmbH

C19: Adsorption of Therapeutic Proteins to Material Surfaces Encountered During Manufacturing, Storage, and Administration, Presented by Rosa A-P., Grenoble INP

C20: Integration of Next-Generation Transposon Vectors with Novel Host Cell Lines, Presented by Ana R., Horizon Discovery Ltd.

C21: Structure-Guided Stabilization of Peptide-HLA-E Complexes Using Non-Natural Amino Acids, Presented by Rob P., Immunocore Ltd.

C22: Screening the Membrane Proteome to Determine Antibody Specificity and De-Risk CAR-T Cell Development, Presented by Rachel F., Integral Molecular

C23: Immune System-Humanized Mouse Models to Predict Outcomes of Human-Specific Immuno-Modulatory Therapies, Presented by Ralph G., Jackson Laboratory

C24: A Translational Model for Drug-Induced Cytokine Release Syndrome-Associated Systemic Toxicity in the Humanized Mouse, Presented by Philip G., Jackson Laboratory

C25: Rapid Screening and Scaled Manufacture of Immunogenic Virus-Like Particles in a Tobacco BY-2 Cell Free Protein Synthesis System, Presented by Jorge AG., LenioBio GmbH

C26: Automated Protein Solubility and Stability Screening for Purification Process Development, Presented by Jean A., Lonza

C27: Deep Learning Enables Viscosity Prediction from Antibody Sequences, Presented by Daniel F., Lonza

C28: GS piggyBac®: Lifting Up Cell Line Construction Expectations to a New Level, Presented by Keerthi C., Lonza

C29: Application of Excipients in Downstream Processing to Improve Protein Purification, Presented by Supriyadi H., Merck KGaA

C30: Exploring the Protein Stabilizing Capability of Surfactants Against Agitation Stress and the Underlying Mechanisms, Presented by Michelle Z., Merck KGaA

C31: Preclinical Efficacy of a Novel Anti-oxMIF/HSG Bispecific Antibody for Pretargeted Radioimmunotherapy, Presented by Alejandro P., OncoOne R&D GmbH

C32: AbXtract: Antibody Discovery in the Cloud, Presented by Suhani N., OpenEye Scienitfic

C33: Rapid Assessment of Aggregation of Biologics in Different Matrices and from Upstream and Downstream Development Process Stages, Presented by Sebastian G., PAIA Biotech

C34: Machine-Learning Guided Mutagenesis for Directed Evolution of Recombinant Proteins, Presented by Norio H., RevolKa Ltd.

C35: Discovery of Novel Therapeutics Against GPCRs, Ion Channels and Transporters, Presented by Robin L., Salipro Biotech AB

C36: Informing the Design of a Bispecific T-Cell Engaging Antibody Targeting Co-Stimulatory Receptors Using a Model-Based Approach, Presented by Celine A., Sanofi

C37: Novel Workflow for Nanobody® Discovery by Implementation of HTRF® Based Concentration Quantification Method, Presented by Kristof M., Sanofi

C38: Design of Experiment Based Optimization of Antibody Purification, Presented by Imme V., Sartorius Stedim Cellca GmbH

C39: CHO Fed-Batch Strategies to Rapidly Increase mAb Titers by 100% Without Sacrificing Product Quality, Presented by Severine F., Selexis SA

C40: Conformational Thermostabilisation of GPCRs by Protein Engineering and Machine Learning, Presented by Jennifer M., Sosei Heptares

C41: Antibody Sequence Analysis – A Multi-Parameter Approach to Enrich for Functional Lead Candidates, Presented by Matteo R., Symphogen

C42: Multispecific cMet x EGFR x VEGF Antibody for Difficult to Treat Cancers, Presented by Mark C., Tavotek Biotherapeutics

C43: Generation of IgM-Directed Antibodies for the Treatment of B Cell Cancers, Presented by Katrin S., Technical University of Darmstadt

C44: C-tag Affinity Tag, from Routine Protein Purification to Use in a cGMP Production Process, Presented by Wannie H., Thermo Fisher Scientific

C45: ExpiSf™ Expression System: A Chemically Defined Baculovirus-Based System for Enhanced Protein and VLP Production in Sf9 Cells, Presented by Maya Y., Thermo Fisher Scientific

C46: Machine-Learning-Assisted Phage Display Application: Functional Variant Mining from Next Generation Sequence Library, Presented by Mitsuo U., Tohoku University

C47: Scaling Structure-Based Antibody Design with Deep Learning Models and Fragment Databases, Presented by Matthew G., University of Cambridge

C48: Efficient Production of Fc Fusion Proteins in the E. coli Cytoplasm, Presented by Aatir T., University of Oulu

C49: Genotyped Functional Screening of Soluble Fab Clones Enables In-Depth Analysis of Mutation Effects, Presented by Sami O., University of Turku

C50: Assessing Stability Differences Between IgG Allelic Variants Using Red Edge Excitation Shift Spectroscopy, Presented by Annmaree W., University of Waikato

C51: Simple and Rapid Analytics for Proteins, Cells & Media in Bioprocessing, Presented by Alessandra P., Valitacell Ltd.

C52: Novel Bispecific Immune Synapse Engagers to Harness Potent T Cell Anti-Tumor Immunity, Presented by Yuval S., Weizmann Institute of Science




V1: Barcode Enabled Antigen Mapping (BEAM) and Single-Cell Sequencing Enables Next-Generation Systems Immunology Analysis of the Post-COVID-19 Immune Landscape, Presented by Peter F., 10x Genomics

V2: Comparing Potential Bispecific Formats of Trastuzumab and a Humanized OKT3, Presented by Ed H., Absolute Antibody

V3: Advanced Antibody Discovery Workflow to Capture Maximum Repertoire Diversity, Presented by Robert D., Abveris

V4: In Vivo VHH Discovery Workflow Based on Immunized Alpaca and Rapid Beacon-Based Single B Cell Screening, Presented by Ryan K., Abveris

V5: Development of One-Step Colorimetric Assays Based on Proximity Proteolysis Reaction for Detecting Various Molecules, Presented by Minji G., Ajou University

V6: High-Throughput Screening of Photocrosslinkable Peptide Libraries for Efficient Site-Specific Modification of Immunoglobulin G, Presented by Yeaji L., Ajou University

V7: Flexible Alternatives To Process Intensification For mAb Purification, Presented by Franklin B., Bio-Rad Laboratories

V8: GMP Ready, CHT Prepacked Columns for High Performance and Stability in Process-Scale Purification, Presented by Jean-Francois D., Bio-Rad Laboratories

V9: A Nanobody Activating Metabotropic Glutamate Receptor 4 Discriminates Between Homo- and Heterodimers, Presented by Anne G-L., BIOVIA, Dassault Systemes

V10: Optimized Antibody Discovery Process Combined with Fine-Grained Engineering, Presented by Kathrin Z., Charles River Laboratories

V11: Biophysical Characterization Approaches for Developability Assessment in Antibody Discovery, Presented by Andreia M., FairJourney Biologics

V12: Characterization and Identification of Potential Critical Quality Attributes (pCQAs) for Enzyme Replacement Therapy of Mucopolysaccharidosis Type IIIA (MPS IIIA), Presented by Cheolwoo N., GC Biopharma

V13: Immune Repertoire Profiling of Autoimmune Diseases, Presented by Kristina D., University of Tuebingen

V14: An Image-Based Proximity Ligation Screen to Assess Co-Localization of Membrane Targets, Presented by Tim H., Genmab B.V.

V15: CD3 Bispecific Antibody Therapy Is Effective in Solid Tumors After Increased T-Cell Infiltration Induced by Vaccines, Presented by Katy L., Genmab B.V.

V16: Aura+: High Throughput, Low volume Product Stability and Purity Analysis for Gene and Cell Therapies, Presented by Paul D., Halo Labs

V17: The Use of In Vitro Assays to Assess and Measure Gene Therapy Immunogenicity, Presented by Sofie P., ImmunXperts, a Q2 Solutions Company

V18: Detailed Structural Analysis of Thermal Denaturation of Monoclonal Antibodies Using JASCO Spectra Manager™ Ver2.5 CFR BeStSel, Presented by Satoko S., JASCO Corporation

V19: Design of a Novel Affibody-Based Prodrug Against EGFR for Selective Tumor-Targeting, Presented by Anna M., KTH Royal Institute of Technology

V20: Comparison of HER2-Targeted Affibody Conjugates Loaded with Auristatin- and Maytansine-Derived Drugs, Presented by Jie Z., KTH Royal Institute of Technology

V21: ALiCE- Simple Reaction Radical Results: Facile Scaling of Eukaryotic Cell-Free Protein Synthesis from Microliter to Liter Volumes with Consistent Yields, Presented by Andreas K., LenioBio GmbH

V22: Lift Your CLC Expectations to a New Level, Presented by Katharina U., Lonza

V23: Novel Therapeutics for Abdominal Pain in Irritable Bowel Syndrome, Presented by Ling-Wei H., National Taiwan University

V24: A Broad-Specificity O-Glycoprotease Enables Improved Analysis of Glycoproteins and Glycopeptides Containing Intact Complex O-Glycans, Presented by Saulius V., New England Biolabs

V25: Biophysical Screening of Antibodies, Presented by Dennis A., Novo Nordisk A/S

V26: OmniChicken® Derived Antibodies to Clptm1: A First-in-Class Therapeutic, Presented by Kristen C., OmniAb, Inc.

V27: ON203: A Novel Bioengineered Anti-oxMIF Antibody with Improved Biophysicochemical Properties and Antitumorigenic Activity, Presented by Gregor R., OncoOne Research & Development GmbH

V28: Separation Sciences to Support Plasmid Analysis, Presented by Ryan H., Pharmaron

V29: A Structural Characterization of a Monoclonal Antibody Therapeutic (Trastuzumab) as Formulated and Under Multiple Conjugation Paradigms, Presented by David S., RedShift Bio

V30: A Lipocalin-Based Molecular ON-Switch to Control CAR T Cells with an Orally Available Drug, Presented by Elise S., St. Anna Children's Cancer Research Institute

V31: Humoral Derived SARS-CoV-2 Nucleocapsid Protein-Specific Single Domain Secondary Antibodies, Presented by Nhlanhla D., Taipei Medical University

V32: Engineering of ultraID , a Compact and Hyperactive Enzyme for Proximity Dependent Biotinylation in Living Cells, Presented by Sebastian B., Technical University of Darmstadt

V33: A Modular Approach for Intracellular Protein Delivery via a Cell-Penetrating Antibody, Presented by Carolin D., Technical University of Darmstadt

V34: Programmable Multispecific DNA-Origami Based T Cell Engagers, Presented by Klaus W., Technical University of Munich

V35: Antibodies with Switchable Affinities, Presented by Kai-Thomas S., Technische Universitat Braunschweig

V36: Developing Highly Potent and Function Antibodies with a High-Throughput Platform, Presented by Kara C., Twist Bioscience

V37: Exploring & Expanding the Natural Human Memory B-Cell CDR H3 Repertoire, Presented by Tony C., Twist Bioscience

V38: Discovery of Diverse Anti-SARS-CoV-2 Antibodies Through a Unique Collaboration, Presented by Mary M., Twist Bioscience

V39: Functional DKK1 Antibodies Demonstrate Antagonistic and Tumor Suppression Activities, Presented by Linya W., Twist Bioscience

V40: Physicochemical and Biological Characterization of Teriparatide Biosimilar, Presented by Sung-Gun K., U1 University

V41: Development of a High-Affinity Anti-Gluten Fab by Merging Chains from Semi-Synthetic (VH) and Immune (VL) Origin, Presented by Aina G., Universidad Complutense de Madrid

V42: Generation of a Single-Chain Variable Fragment (scFv) Library for the Detection of Hen's Egg Ovomucoid in Foods, Presented by Santiago R., Universidad Complutense de Madrid

V43: Biophysical Characterization of Second-Generation Myc Inhibitors and Determination of Their Cell-Penetration Properties in Cancer Cells, Presented by Hugo T., Universitat Autonoma de Barcelona

V44: A Unique Screening System to Develop E. coli Mutants for the Efficient Production of Difficult to Express Therapeutic Proteins, Presented by Hiroyuki K., Université catholique de Louvain

V45: Integration of Clinical, Laboratory and Multi-Omics Data to Leverage Machine Learning for Diagnostics, Presented by Jan K., University of Applied Sciences and Arts Northwestern Switzerland - FHNW

V46: Personalized Medical Platform to Support Diagnosis of Autoimmune Diseases with Artificial Intelligence, Presented by Patrick M., University of Applied Sciences and Arts Northwestern Switzerland - FHNW

V47: Computational Deconvolution of the Dengue Immune Response Complexity with Identification of Novel Broadly Neutralizing Antibodies, Presented by Eriberto N., University of Applied Sciences and Arts Northwestern Switzerland - FHNW

V48: Innovative Prototype for Visible Particle Detection, Characterization and Chemical Identification in Closed Container, Presented by Ilias A., University of Basel

V49: Antibody Scanning of Beta-2 Microglobulin, Presented by Monty A., University of Cambridge

V50: Humanness Assessment with Machine Learning for De Novo Nanobody Design, Presented by Aubin R., University of Cambridge

V52: PhosphoFlowSeq - A Novel High-Throughput Kinase Activity Assay for the Identification of Drug Resistance Mutations in EGFR, Presented by Magdalena T., University of Natural Resources and Life Sciences - BOKU

V53: Incorporating Machine Learning into a VHH Candidate Discovery Pipeline, Presented by Ben W., University of Nottingham

V54: Creation of Monoclonal Antibodies via Phage Display to Target Immunoreactive Part of LPS, Presented by Alexandra F., University of Salzburg

V55: Chemical Filtering: A Post-Transfection Directed Evolution Strategy to Improve Productivity of Difficult-to-Express Antibodies in CHO Cell Lines, Presented by Chillel J., University of Sheffield

V56: High-Fidelity Large-Diversity Monoclonal Mammalian Cell Libraries by aRMCE, Presented by Xin G., University of Texas Health Science Center at Houston

V57: DLS Microviscometry of Concentrated Protein Solutions, Presented by Coline B., LS Instruments AG

V58: Automated Production of Viral Vectors for Cell and Gene TherapyPresented by Sebastian K., Genedata AG

V59: Designing and Screening Complex Proteins with Novel Capabilities at Industrial ScalePresented by Eric A., Genedata AG

V60: An Antibody from a Snakebite Hyperimmune Subject Recognizes 3-Finger Toxins in Venom from Multiple Snake Species, Presented by Baoshan Z., National Institutes of Health, National Institute of Allergy and Infectious Diseases

V61: Antibody Degradation Affects Polysorbate Quantification, Presented by Vincentius H., Janssen Biologics BV

V62: Cysteine-to-Lysine Antibody Fragment ConjugationPresented by Muhammed H., University College London

V63: Improved Pharmacokinetics of Broadly Neutralizing HIV-1 Antibodies Achieved by Reduction of Net Positive Charge on the Variable Domain, Presented by Young Do K., National Institutes of Health, Vaccine Research Center